Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease
dc.contributor.author | Güney, İbrahim | |
dc.contributor.author | Selçuk, N. Yılmaz | |
dc.contributor.author | Altıntepe, Lütfullah | |
dc.contributor.author | Atalay, Hüseyin | |
dc.contributor.author | Başarali, M. Kemal | |
dc.contributor.author | Büyükbaş, Sadık | |
dc.date.accessioned | 2020-03-26T17:37:52Z | |
dc.date.available | 2020-03-26T17:37:52Z | |
dc.date.issued | 2009 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description.abstract | Aims. Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. Methods. This prospective study included 30 non-diabetic chronic kidney disease (CKD) patients treated with ACEIs and/or ARBs. The patients were divided into two groups that are similar in terms of demographic parameters. 25 mg of spironolactone was added to group 1 (n = 15) for six months, though it was not administered to group 2 (n = 15). Creatinine (U-Cr), protein (U-Prot), and TGF-beta 1 (U-TGF-beta 1) were measured in spot urine sample in the beginning of study and six months later. Results. Twenty-four patients completed the study. There were no significant changes in mean blood pressure, glomerular filtration rate, creatinine, albumin, and plasma aldosterone concentrations during the observation period in either group. U-Prot/U-Cr (mg/mg Cr) was reduced from 2.43 +/- 4.85 at baseline to 1.66 +/- 3.51 at sixth month (p = 0.003) in group 1. In addition, U-TGF-beta 1/U-Cr (ng/mg Cr) was also reduced from 22.50 +/- 6.65 at baseline to 17.78 +/- 10.94 at sixth month (p = 0.041) in the same group. U-TGF-beta 1/U-Cr and U-Prot/U-Cr ratios after the sixth month were not found significant compared with baseline values in group 2. Conclusion. Spironolactone reduced both proteinuria and urinary TGF-beta 1 excretion in CKD patients. We consider that spironolactone would be beneficial to prevent progression of renal fibrosis in CKD. | en_US |
dc.description.sponsorship | Ali Raif Drug Industry A.C. | en_US |
dc.description.sponsorship | This study was supported by Ali Raif Drug Industry A.C. for providing TGF-beta 1 and aldosterone kits. | en_US |
dc.identifier.doi | 10.3109/08860220903150312 | en_US |
dc.identifier.endpage | 784 | en_US |
dc.identifier.issn | 0886-022X | en_US |
dc.identifier.issn | 1525-6049 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.pmid | 19925284 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 779 | en_US |
dc.identifier.uri | https://dx.doi.org/10.3109/08860220903150312 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/23284 | |
dc.identifier.volume | 31 | en_US |
dc.identifier.wos | WOS:000273987900002 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | TAYLOR & FRANCIS LTD | en_US |
dc.relation.ispartof | RENAL FAILURE | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.subject | TGF-beta 1 | en_US |
dc.subject | chronic kidney disease | en_US |
dc.subject | spironolactone | en_US |
dc.subject | proteinuria | en_US |
dc.title | Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease | en_US |
dc.type | Article | en_US |